Which has preferable valuation & earnings, BBIO or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 31.73 -$724.93M -$3.57 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is BBIO or PBLS more profitable?

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% Parabilis Medicines N/A N/A N/A

Does the media favor BBIO or PBLS?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for BridgeBio Pharma and 4 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat BridgeBio Pharma's score of 0.29 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PBLS or ASND?

Parabilis Medicines has higher earnings, but lower revenue than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Ascendis Pharma A/S $1.05B 15.09 -$258M $12.89 19.65

Does the media favor PBLS or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 4 mentions for Parabilis Medicines. Ascendis Pharma A/S's average media sentiment score of 1.04 beat Parabilis Medicines' score of 0.41 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EXEL or PBLS?

Exelixis has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.78 $782.57M $3.18 17.01 Parabilis Medicines N/A N/A N/A N/A N/A

Does the media refer more to EXEL or PBLS?

In the previous week, Exelixis had 12 more articles in the media than Parabilis Medicines. MarketBeat recorded 16 mentions for Exelixis and 4 mentions for Parabilis Medicines. Exelixis' average media sentiment score of 1.18 beat Parabilis Medicines' score of 0.41 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PBLS or BMRN?

BioMarin Pharmaceutical has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A BioMarin Pharmaceutical $3.22B 4.01 $348.90M $0.37 180.27

Does the media prefer PBLS or BMRN?

In the previous week, BioMarin Pharmaceutical had 30 more articles in the media than Parabilis Medicines. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 4 mentions for Parabilis Medicines. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Parabilis Medicines' score of 0.41 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ARWR or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arrowhead Pharmaceuticals $829.45M 14.79 -$1.63M -$2.25 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media favor ARWR or PBLS?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for Parabilis Medicines. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Parabilis Medicines' score of 0.41 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Parabilis Medicines (PBLS) Competitors

$39.36 -0.22 (-0.56%)

As of 08/21/2026 04:00 PM Eastern

Compare

PBLS vs. BBIO, ASND, EXEL, BMRN, and ARWR

Should you buy Parabilis Medicines stock or one of its competitors? Parabilis Medicines's main competitors and comparable companies include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Parabilis Medicines compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BridgeBio Pharma currently has a consensus price target of $100.79, indicating a potential upside of 23.67%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 5.86%. Given BridgeBio Pharma's higher possible upside, research analysts clearly believe BridgeBio Pharma is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Parabilis Medicines has lower revenue, but higher earnings than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, BridgeBio Pharma had 2 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for BridgeBio Pharma and 4 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat BridgeBio Pharma's score of 0.29 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Parabilis Medicines	N/A	N/A	N/A

Summary

BridgeBio Pharma beats Parabilis Medicines on 6 of the 11 factors compared between the two stocks.

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Parabilis Medicines (NASDAQ:PBLS) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Parabilis Medicines currently has a consensus price target of $41.67, suggesting a potential upside of 5.86%. Ascendis Pharma A/S has a consensus price target of $300.33, suggesting a potential upside of 18.57%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Ascendis Pharma A/S has a net margin of 70.99% compared to Parabilis Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Parabilis Medicines has higher earnings, but lower revenue than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Ascendis Pharma A/S	$1.05B	15.09	-$258M	$12.89	19.65

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 4 mentions for Parabilis Medicines. Ascendis Pharma A/S's average media sentiment score of 1.04 beat Parabilis Medicines' score of 0.41 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Parabilis Medicines on 10 of the 10 factors compared between the two stocks.

How does Parabilis Medicines compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Exelixis has a net margin of 35.33% compared to Parabilis Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Parabilis Medicines	N/A	N/A	N/A

Exelixis has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Exelixis had 12 more articles in the media than Parabilis Medicines. MarketBeat recorded 16 mentions for Exelixis and 4 mentions for Parabilis Medicines. Exelixis' average media sentiment score of 1.18 beat Parabilis Medicines' score of 0.41 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Exelixis presently has a consensus price target of $50.07, indicating a potential downside of 7.42%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 5.86%. Given Parabilis Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Parabilis Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Exelixis beats Parabilis Medicines on 9 of the 11 factors compared between the two stocks.

How does Parabilis Medicines compare to BioMarin Pharmaceutical?

Parabilis Medicines (NASDAQ:PBLS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

In the previous week, BioMarin Pharmaceutical had 30 more articles in the media than Parabilis Medicines. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 4 mentions for Parabilis Medicines. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Parabilis Medicines' score of 0.41 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines presently has a consensus price target of $41.67, suggesting a potential upside of 5.86%. BioMarin Pharmaceutical has a consensus price target of $88.83, suggesting a potential upside of 33.17%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

BioMarin Pharmaceutical has a net margin of 2.14% compared to Parabilis Medicines' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Parabilis Medicines on 11 of the 12 factors compared between the two stocks.

How does Parabilis Medicines compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Parabilis Medicines has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 4 mentions for Parabilis Medicines. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Parabilis Medicines' score of 0.41 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals currently has a consensus price target of $97.33, suggesting a potential upside of 11.74%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 5.86%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Parabilis Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Parabilis Medicines' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Parabilis Medicines	N/A	N/A	N/A

Summary

Arrowhead Pharmaceuticals beats Parabilis Medicines on 7 of the 12 factors compared between the two stocks.

Get Parabilis Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBLS vs. The Competition

Export

Metric	Parabilis Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.65B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	N/A	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	N/A	16.80	13.05	6.20
Net Income	N/A	-$12.50M	$3.47B	$348.59M
7 Day Performance	6.18%	3.29%	2.09%	0.08%
1 Month Performance	19.96%	8.23%	6.64%	3.88%
1 Year Performance	N/A	55.05%	25.02%	16.98%

Parabilis Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBLS Parabilis Medicines	2.084 of 5 stars	$39.36 -0.6%	$41.67 +5.9%	N/A	$4.65B	N/A	N/A	N/A
BBIO BridgeBio Pharma	3.2352 of 5 stars	$82.94 -1.2%	$100.79 +21.5%	+66.1%	$16.41B	$502.08M	N/A	400	Insider Trade
ASND Ascendis Pharma A/S	4.6059 of 5 stars	$254.81 -1.9%	$300.33 +17.9%	+30.4%	$16.19B	$814.57M	19.77	1,189	Positive News Earnings Report Analyst Forecast Insider Trade
EXEL Exelixis	3.3988 of 5 stars	$53.69 -1.3%	$50.07 -6.7%	+40.0%	$13.48B	$2.32B	16.88	1,077	News Coverage Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.7599 of 5 stars	$67.68 -2.4%	$88.83 +31.2%	+13.9%	$13.42B	$3.22B	182.92	3,221	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBLS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Parabilis Medicines (PBLS) Competitors

PBLS vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Parabilis Medicines compare to BridgeBio Pharma?

Summary

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Summary

How does Parabilis Medicines compare to Exelixis?

Summary

How does Parabilis Medicines compare to BioMarin Pharmaceutical?

Summary

How does Parabilis Medicines compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Parabilis Medicines (PBLS) Competitors

PBLS vs. BBIO, ASND, EXEL, BMRN, and ARWR

How does Parabilis Medicines compare to BridgeBio Pharma?

Do insiders & institutionals have more ownership in BBIO or PBLS?

Do analysts recommend BBIO or PBLS?

Which has preferable valuation & earnings, BBIO or PBLS?

Does the media favor BBIO or PBLS?

Is BBIO or PBLS more profitable?

Summary

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Do analysts rate PBLS or ASND?

Is PBLS or ASND more profitable?

Which has higher earnings & valuation, PBLS or ASND?

Does the media favor PBLS or ASND?

Summary

How does Parabilis Medicines compare to Exelixis?

Is EXEL or PBLS more profitable?

Which has higher valuation and earnings, EXEL or PBLS?

Does the media refer more to EXEL or PBLS?

Do insiders and institutionals have more ownership in EXEL or PBLS?

Do analysts rate EXEL or PBLS?

Summary

How does Parabilis Medicines compare to BioMarin Pharmaceutical?

Does the media prefer PBLS or BMRN?

Do analysts recommend PBLS or BMRN?

Is PBLS or BMRN more profitable?

Which has higher earnings & valuation, PBLS or BMRN?

Do insiders & institutionals believe in PBLS or BMRN?

Summary

How does Parabilis Medicines compare to Arrowhead Pharmaceuticals?

Which has better valuation and earnings, ARWR or PBLS?

Does the media favor ARWR or PBLS?

Do analysts rate ARWR or PBLS?

Do insiders & institutionals hold more shares of ARWR or PBLS?

Is ARWR or PBLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools